Advisors voted overwhelmingly against approving MDMA for PTSD therapy due to flaws in trials, including missing data and bias, despite initially positive results.
Double-blind trials were essentially unblinded, with participants and therapists aware of who received MDMA, leading to significant bias concerns and invalidating positive outcomes.
[
add
]
[
|
|
...
]